Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

17.19
-0.0900-0.52%
Volume:22.15K
Turnover:379.39K
Market Cap:1.05B
PE:-10.46
High:17.35
Open:17.13
Low:16.97
Close:17.28
52wk High:35.34
52wk Low:12.12
Shares:61.14M
Float Shares:42.53M
Volume Ratio:0.95
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6429
EPS(LYR):-1.8336
ROE:-10.70%
ROA:-8.80%
PB:1.13
PE(LYR):-9.37

Loading ...

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX)

TIPRANKS
·
Jun 25

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

Janux Therapeutics reports departure of Chief Medical Officer

TIPRANKS
·
Jun 24

Janux Therapeutics CMO William Go departs under severance plan terms

Reuters
·
Jun 24

Janux Therapeutics Reports Results of 2026 Annual Meeting

TIPRANKS
·
Jun 13

Janux Therapeutics shareholders elect two directors at annual meeting

Reuters
·
Jun 13

Janux VP Accounting Maria Dobek sells 2,038 shares worth $28,874.46

Reuters
·
May 14

Janux Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating

MT Newswires Live
·
May 08

Janux Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
May 08

Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler

TIPRANKS
·
May 08

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Janux Therapeutics Inc (JANX) and Progyny (PGNY)

TIPRANKS
·
May 08

Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14

TIPRANKS
·
May 08

Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward

TIPRANKS
·
May 08

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Janux Therapeutics Q1 EPS $(0.39) Beats $(0.53) Estimate, Sales $3.733M Miss $3.833M Estimate

Benzinga Earnings
·
May 08

Janux Q1 FY26 net loss widens to $24.4 million; R&D expenses rise to $26.8 million

Reuters
·
May 08

BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.39

Reuters
·
May 08

Janux Therapeutics Q1 Net Income USD -24.361 Million

THOMSON REUTERS
·
May 08